COMPANY UPDATES
12
Apr
2018
Novoheart Founder & CEO Dr. Ronald Li honored with 2017 Distinguished Alumnus Award by the University of Waterloo

Novoheart is pleased to announce that Dr. Ronald Li, Founder and CEO of the Company, has been awarded with the 2017 Distinguished Alumnus Award by the University of Waterloo, Canada, from which he graduated with a B.Sc. in 1994. As one of two recipients of the award from the Faculty of Science, Dr. Li is recognized for his two decades of research on human cardiac tissue engineering, and his continuous efforts to translate and commercialize basic findings into tangible applications and community benefits, including the founding of Novoheart in 2014.

29
Mar
2018
Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner

Novoheart is pleased to announce that it has filed a patent application on the use of its proprietary MyHeartTM Platform of human bioengineered heart tissues to create disease models for neurological diseases in which afflicted patients suffer and often die from cardiac dysfunction. The IP, which is solely owned by Novoheart, was developed as part of the Company’s successfully completed second contract with a Global Pharma partner.

14
Mar
2018
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park

Novoheart is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.

08
Mar
2018
Novoheart's Landmark, Peer-Reviewed Study Published, Recognizing the Effectiveness of the World's First and Only Human Heart-in- a-Jar

Novoheart is pleased to announce that it has published a comprehensive study of the world's first human heart-in- a-jar, in the prestigious bioengineering journal Biomaterials. The peer-reviewed paper showcases the human heart-in-a-jar's unique ability to recapitulate multiple important and complex biological properties of the native human heart, including clinically recognized responses to a variety of pharmacological compounds and interventions.